ArticleInternational dental journal2026
Developing a Silver Nanocomposite With Quorum-Quenching Enzyme Ag-Est816 to Prevent Periodontitis.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Quorum-quenching enzymes as next-generation antibiofilm therapeutics: mechanisms, applications, and future perspectives.World journal of microbiology & biotechnology · 2026Review
- Quorum sensing in oral multispecies biofilms: from interkingdom communication to therapeutic targeting.Frontiers in microbiology · 2026Review
- Preventing peri-implantitis with Ag-Est816 nanocomposite: modified rat model and preventive assessment.Frontiers in oral health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to synthesise a novel silver nanocomposite incorporating quorum-quenching enzyme N-acyl-homoserine lactone-lactonase Est816 (Ag-Est816) to inhibit periodontal biofilm formation.
methodsA one-pot reaction was employed to synthesise Ag-Est816 using silver nitrate, branched polyethyleneimine, and Est816. Ag-Est816 was characterized using dynamic light scattering (DLS), transmission electron microscopy (TEM), and X-ray photoelectron spectroscopy (XPS). Material stability was assessed by inductively coupled plasma spectrometry to determine the cumulative release rate of Ag⁺ and by a colorimetric enzyme activity assay to determine the retention rate of enzyme activity. Cytotoxicity toward human gingival fibroblasts (HGFs) was assessed using the Cell Counting Kit-8 (CCK-8) assay and immunofluorescent staining. Biomass of periodontal biofilm (Porphyromonas gingivalis and Streptococcus sanguinis) was analyzed using a crystal violet staining assay; viability and thickness were examined with confocal laser scanning microscopy. The biofilm and bacterial cells were examined using scanning electron microscopy (SEM) and TEM. Phosphate-buffered saline (PBS) served as the control.
resultsDLS and TEM revealed spherical particles with a diameter of 98 ± 5 nm. XPS confirmed silver coordination bonds formation. The cumulative release rate of Ag⁺ was 0.19 ± 0.01%. The retention rate of enzyme activity was 93.3 ± 0.4% at 48 hours. Ag-Est816 was non-cytotoxic to HGFs, as evidenced by normal cytoskeletal morphology and no difference in cell proliferation compared to the PBS group (P = .36). The biomass in the Ag-Est816 and PBS groups was 0.82 ± 0.05 and 2.77 ± 0.16 (P< .001), and their live/dead ratios were 46 ± 6% and 80 ± 5%, respectively (P< .001). SEM revealed dispersed biofilms, and TEM showed bacterial cells with disrupted membranes in the Ag-Est816 group.
conclusionThis study developed a novel Ag-Est816 antibacterial nanocomposite effective against periodontal biofilm. CLINICAL SIGNIFICANCE: Ag-Est816 warrants future investigation for the localized control of periodontal biofilms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.